TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07859007: A Phase 1, Open-Label, Fixed Sequence, Drug-Drug Interaction Study Assessing the Potential CYP3A Induction Effect of Brensocatib on the Pharmacokinetics of Midazolam in Healthy Participants

Sponsor: Insmed Incorporated · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 26 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$5,147,328

Rescue Site Savings

+$3,386,400

Unlock Full NCT07859007 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07859007 Rescue Dossier →